If gene therapy works for Wilson disease, can I stop my daily medication?

The honest short answer is: we do not know yet, and anyone who tells you otherwise is getting ahead of the evidence. Gene therapy for Wilson disease is genuinely promising — researchers have produced exciting results in mice and early laboratory models — but no therapy has yet reached the point where your specialist could say “you can stop your chelator now.”¹ The big dream — one treatment that restores normal copper handling so you can live free of daily pills and eat whatever you want — is scientifically coherent, but it is still a goal rather than a current option.

What gene therapy for Wilson disease is actually trying to do

Wilson disease is caused by mutations in the ATP7B gene, which encodes a copper-transporting protein in liver cells.² Without a working copy of ATP7B, copper accumulates in the liver, brain, kidneys, and other organs. Current medications — penicillamine, trientine, zinc salts — manage copper by either pulling it out of the body or blocking its absorption. They work, but they do not fix the underlying defect; you keep needing them for life.

Gene therapy takes a different approach: deliver a working copy of ATP7B directly into liver cells. If enough cells take it up and express the protein correctly, the liver could start doing what it is supposed to do — package copper for excretion through bile — without any drug in the picture. In theory, that would eliminate both the need for medication and the need for a low-copper diet.³

Where the science currently stands

In 2019, Greig and colleagues published results from a gene therapy approach using a viral vector to deliver functional ATP7B into a mouse model of Wilson disease. They showed improved copper metabolism and reduced liver damage in treated animals.³ This kind of preclinical work is necessary and encouraging — but a result in mice is a very early step.

Translating liver-directed gene therapy into humans is harder than it sounds. The liver is enormous compared with a mouse liver, immune reactions to viral delivery vehicles are more complex in people, and the duration of gene expression — whether a single treatment lasts years or fades over time — is still being worked out across all liver-directed gene therapy programs, not just Wilson disease.¹⁴

Researchers have outlined several barriers specific to Wilson disease: the ATP7B gene itself is large, which creates packaging challenges for some delivery vehicles; the fact that Wilson disease is not immediately fatal gives regulatory agencies less flexibility in tolerating unknown long-term risks; and unlike some genetic liver diseases, Wilson disease already has treatments that work reasonably well, so a gene therapy must demonstrate clear benefits over existing options before approval.⁴

As of the most recent AASLD practice guidance (2022), gene therapy for Wilson disease is described as an area of active investigation, but no human clinical trial had completed with data sufficient to change standard-of-care recommendations.⁵

What about other “next generation” treatments?

Gene therapy is not the only emerging approach. A drug called bis-choline tetrathiomolybdate (ALXN1840, formerly WTX101) has been studied in a Phase 3 trial — this is a copper chelator with a different mechanism from penicillamine or trientine, and it works at the cellular level rather than simply pulling copper from blood.⁶ While this is exciting, it is still a daily (or periodic) drug, not a cure. It does not restore normal ATP7B function.

CRISPR-based gene editing approaches are also being studied in the broader field of genetic liver disease. Whether they will be applied to Wilson disease, and on what timeline, is genuinely unknown.

So could I ever eat normally and stop my medication?

If a curative gene therapy reaches clinical practice — which could realistically take a decade or more to prove safe and effective in humans — then yes: the expectation would be that copper metabolism normalizes, making daily copper-lowering drugs unnecessary. Diet restrictions might also ease substantially, though some caution about very high-copper foods would likely remain advisable until long-term outcomes are better understood.

Here is the difficulty with planning your life around this: timelines for novel therapies are notoriously hard to predict. Many therapies that look transformative in mice take 10–20 years to become standard of care — if they make it at all. Regulatory review, manufacturing scale-up, insurance coverage, and post-market safety monitoring all take time. Patients who are managing well on current therapy should not defer or compromise their current regimen hoping that a cure is “right around the corner.”

What you can do right now

The best thing you can do if you are interested in gene therapy trials is to find out whether any are recruiting. ClinicalTrials.gov (run by the US National Library of Medicine) lists active studies, and your specialist should know what is enrolling in your region. Participation in well-designed trials is one of the most meaningful ways patients contribute to moving this science forward.

In the meantime, the medications and monitoring that keep you stable today are not something to deprioritize. Current treatments — when taken consistently — allow most people with Wilson disease to live a normal lifespan. See medications overview for more on how the current options compare, and diet and copper for practical guidance on what the diet recommendations actually mean day to day.

This article is for patient education purposes only and is not a substitute for advice from your hepatologist or specialist. Gene therapy research is a fast-moving field; your care team can tell you what studies are currently available and whether you might be eligible to participate.

References